5-异丙基-1-甲基-2-硝基-1H-咪唑 | 23571-34-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-异丙基-1-甲基-2-硝基-1H-咪唑
• 英文名称: 1-Methyl-2-nitro-5-isopropylimidazol
• 英文别名: 5-Isopropyl-1-methyl-2-nitroimidazol；1-Methyl-5-isopropyl-2-nitroimidazol；5-isopropyl-1-methyl-2-nitro-1H-imidazole；5-Isopropyl-1-methyl-2-nitro-1H-imidazole；1-methyl-2-nitro-5-propan-2-ylimidazole
• CAS: 23571-34-8
• 化学式: C₇H₁₁N₃O₂
• 分子量: 169.183
• InChiKey: NOXMCEHYBLYCTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  63.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933290090

文献信息

• [EN] NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER<br/>[FR] NOUVELLES AMINOPYRIDINES ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2022064430A1

  公开（公告）日：2022-03-31

  The invention relates to substituted imidazo[4,5-c]pyridine-2-one compounds of Formula (I) and prodrugs of said compounds. Compounds of Formula (I) selectively inhibit the activity of DNA-dependent protein kinase (DNA-PK) and are therefore useful in the treatment of diseases in which inhibition of DNA-PK is beneficial.

  这项发明涉及Formula (I)的取代咪唑并[4,5-c]吡啶-2-酮化合物以及这些化合物的前药。Formula (I)的化合物选择性地抑制DNA-依赖性蛋白激酶(DNA-PK)的活性，因此在治疗需要抑制DNA-PK的疾病中具有用处。
• External preparation for skin diseases containing nitroimidazole
  申请人：——

  公开号：US20030092754A1

  公开（公告）日：2003-05-15

  An external preparation for skin disease which comprises a nitroimidazole derivative represented by the following formula (I): 1 wherein R 1 , R 3 and R 4 may be the same or different and represent a hydrogen atom, a nitro group, a lower alkyl group, a substituted lower alkyl group, a lower alkenyl group, or a substituted lower alkenyl group; and R 2 represents a hydrogen atom, a lower alkyl group, a substituted lower alkyl group and a lower alkenyl group or a substituted lower alkenyl group, provided that any one of R 1 , R 3 and R 4 is a nitro group.

  一种外用制剂，用于皮肤疾病，包括以下式(I)所代表的硝基咪唑衍生物：1其中R1、R3和R4可以相同也可以不同，并表示氢原子、硝基、低烷基、取代的低烷基、低烯基或取代的低烯基；R2表示氢原子、低烷基、取代的低烷基和低烯基或取代的低烯基，只要R1、R3和R4中的任何一个是硝基。
• Phosphoramidate Alkylator Prodrugs
  申请人：Matteucci Mark

  公开号：US20110251159A1

  公开（公告）日：2011-10-13

  Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.

  磷酰胺烷基化剂前药可单独或与一个或多个抗肿瘤药物联合使用，用于治疗癌症。
• PHOSPHORAMIDATE ALKYLATOR PRODRUGS
  申请人：Threshold Pharmaceuticals, Inc.

  公开号：US20130303778A1

  公开（公告）日：2013-11-14

  Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.

  磷酰胺烷基化剂前药可单独或与一个或多个抗肿瘤药物联合使用以治疗癌症。
• NITROIMIDAZOLE EXTERNAL PREPARATIONS FOR DERMATOSIS
  申请人：SHOEI CO., LTD.

  公开号：EP1206937A1

  公开（公告）日：2002-05-22

  An external preparation for skin disease which comprises a nitroimidazole derivative represented by the following formula (I): wherein R1, R3 and R4 may be the same or different and represent a hydrogen atom, a nitro group, a lower alkyl group, a substituted lower alkyl group, a lower alkenyl group, or a substituted lower alkenyl group; and R2 represents a hydrogen atom, a lower alkyl group, a substituted lower alkyl group and a lower alkenyl group or a substituted lower alkenyl group, provided that any one of R1, R3 and R4 is a nitro group.

  一种治疗皮肤病的外用制剂，它包括由下式(I)代表的硝基咪唑衍生物： 其中 R1、R3 和 R4 可以相同或不同，代表氢原子、硝基、低级烷基、取代的低级烷基、低级烯基或取代的低级烯基；R2 代表氢原子、低级烷基、取代的低级烷基和低级烯基或取代的低级烯基，条件是 R1、R3 和 R4 中的任何一个是硝基。